Interferon alpha/beta signaling
gene
reagent
sample publication
sample review
2 5 oligoadenylate synthetase like
2'-5'-oligoadenylate synthetase like
Egr-1
early growth response 1
total:28
Monocyte 15-lipoxygenase gene expression requires ERK1/2 MAPK activity. 2010 to the paper
Santa Cruz Biotechnology rabbit anti-human Egr-1 antibody was used to perform immunoblotting in order to study the important role of ERK1/2 in mediating IL-13-induced monocyte 15-LO expression. more
GBP2
guanylate binding protein 2
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA E
major histocompatibility complex, class I, E
total:12
ESCRT-III governs the Aurora B-mediated abscission checkpoint through CHMP4C. 2012 to the paper
Serotec FITC-conjugated anti-MHC-I was used to perform flow cytometry in order to show that cell abscission mediated by Aurora B was regulated by ESCRT-III. more
HLA-A
major histocompatibility complex, class I, A
total:8
Long-term engraftment and expansion of tumor-derived memory T cells following the implantation of non-disrupted pieces of human lung tumor into NOD-scid IL2Rgamma(null) mice. 2008 to the paper
Santa Cruz Biotechnology anti-HLA-A(A-18) antibody was used to perform immunohistochemistry in order to study tumor and tumor-stromal cell interactions. more
HLA-A
major histocompatibility complex, class I, A
total:8
Long-term engraftment and expansion of tumor-derived memory T cells following the implantation of non-disrupted pieces of human lung tumor into NOD-scid IL2Rgamma(null) mice. 2008 to the paper
Santa Cruz Biotechnology anti-HLA-A(A-18) antibody was used to perform immunohistochemistry in order to study tumor and tumor-stromal cell interactions. more
HLA-A
major histocompatibility complex, class I, A
total:8
Long-term engraftment and expansion of tumor-derived memory T cells following the implantation of non-disrupted pieces of human lung tumor into NOD-scid IL2Rgamma(null) mice. 2008 to the paper
Santa Cruz Biotechnology anti-HLA-A(A-18) antibody was used to perform immunohistochemistry in order to study tumor and tumor-stromal cell interactions. more
HLA-A
major histocompatibility complex, class I, A
total:8
Long-term engraftment and expansion of tumor-derived memory T cells following the implantation of non-disrupted pieces of human lung tumor into NOD-scid IL2Rgamma(null) mice. 2008 to the paper
Santa Cruz Biotechnology anti-HLA-A(A-18) antibody was used to perform immunohistochemistry in order to study tumor and tumor-stromal cell interactions. more
HLA-A
major histocompatibility complex, class I, A
total:8
Long-term engraftment and expansion of tumor-derived memory T cells following the implantation of non-disrupted pieces of human lung tumor into NOD-scid IL2Rgamma(null) mice. 2008 to the paper
Santa Cruz Biotechnology anti-HLA-A(A-18) antibody was used to perform immunohistochemistry in order to study tumor and tumor-stromal cell interactions. more
HLA-A
major histocompatibility complex, class I, A
total:8
Long-term engraftment and expansion of tumor-derived memory T cells following the implantation of non-disrupted pieces of human lung tumor into NOD-scid IL2Rgamma(null) mice. 2008 to the paper
Santa Cruz Biotechnology anti-HLA-A(A-18) antibody was used to perform immunohistochemistry in order to study tumor and tumor-stromal cell interactions. more
HLA-A
major histocompatibility complex, class I, A
total:8
Long-term engraftment and expansion of tumor-derived memory T cells following the implantation of non-disrupted pieces of human lung tumor into NOD-scid IL2Rgamma(null) mice. 2008 to the paper
Santa Cruz Biotechnology anti-HLA-A(A-18) antibody was used to perform immunohistochemistry in order to study tumor and tumor-stromal cell interactions. more
HLA-A
major histocompatibility complex, class I, A
total:8
Long-term engraftment and expansion of tumor-derived memory T cells following the implantation of non-disrupted pieces of human lung tumor into NOD-scid IL2Rgamma(null) mice. 2008 to the paper
Santa Cruz Biotechnology anti-HLA-A(A-18) antibody was used to perform immunohistochemistry in order to study tumor and tumor-stromal cell interactions. more
HLA-A
major histocompatibility complex, class I, A
total:8
Long-term engraftment and expansion of tumor-derived memory T cells following the implantation of non-disrupted pieces of human lung tumor into NOD-scid IL2Rgamma(null) mice. 2008 to the paper
Santa Cruz Biotechnology anti-HLA-A(A-18) antibody was used to perform immunohistochemistry in order to study tumor and tumor-stromal cell interactions. more
HLA-A
major histocompatibility complex, class I, A
total:8
Long-term engraftment and expansion of tumor-derived memory T cells following the implantation of non-disrupted pieces of human lung tumor into NOD-scid IL2Rgamma(null) mice. 2008 to the paper
Santa Cruz Biotechnology anti-HLA-A(A-18) antibody was used to perform immunohistochemistry in order to study tumor and tumor-stromal cell interactions. more
HLA-A
major histocompatibility complex, class I, A
total:8
Long-term engraftment and expansion of tumor-derived memory T cells following the implantation of non-disrupted pieces of human lung tumor into NOD-scid IL2Rgamma(null) mice. 2008 to the paper
Santa Cruz Biotechnology anti-HLA-A(A-18) antibody was used to perform immunohistochemistry in order to study tumor and tumor-stromal cell interactions. more
HLA-A
major histocompatibility complex, class I, A
total:8
Long-term engraftment and expansion of tumor-derived memory T cells following the implantation of non-disrupted pieces of human lung tumor into NOD-scid IL2Rgamma(null) mice. 2008 to the paper
Santa Cruz Biotechnology anti-HLA-A(A-18) antibody was used to perform immunohistochemistry in order to study tumor and tumor-stromal cell interactions. more
HLA-A
major histocompatibility complex, class I, A
total:8
Long-term engraftment and expansion of tumor-derived memory T cells following the implantation of non-disrupted pieces of human lung tumor into NOD-scid IL2Rgamma(null) mice. 2008 to the paper
Santa Cruz Biotechnology anti-HLA-A(A-18) antibody was used to perform immunohistochemistry in order to study tumor and tumor-stromal cell interactions. more
HLA-A
major histocompatibility complex, class I, A
total:8
Long-term engraftment and expansion of tumor-derived memory T cells following the implantation of non-disrupted pieces of human lung tumor into NOD-scid IL2Rgamma(null) mice. 2008 to the paper
Santa Cruz Biotechnology anti-HLA-A(A-18) antibody was used to perform immunohistochemistry in order to study tumor and tumor-stromal cell interactions. more
HLA-A
major histocompatibility complex, class I, A
total:8
Long-term engraftment and expansion of tumor-derived memory T cells following the implantation of non-disrupted pieces of human lung tumor into NOD-scid IL2Rgamma(null) mice. 2008 to the paper
Santa Cruz Biotechnology anti-HLA-A(A-18) antibody was used to perform immunohistochemistry in order to study tumor and tumor-stromal cell interactions. more
HLA-A
major histocompatibility complex, class I, A
total:8
Long-term engraftment and expansion of tumor-derived memory T cells following the implantation of non-disrupted pieces of human lung tumor into NOD-scid IL2Rgamma(null) mice. 2008 to the paper
Santa Cruz Biotechnology anti-HLA-A(A-18) antibody was used to perform immunohistochemistry in order to study tumor and tumor-stromal cell interactions. more
HLA-A
major histocompatibility complex, class I, A
total:8
Long-term engraftment and expansion of tumor-derived memory T cells following the implantation of non-disrupted pieces of human lung tumor into NOD-scid IL2Rgamma(null) mice. 2008 to the paper
Santa Cruz Biotechnology anti-HLA-A(A-18) antibody was used to perform immunohistochemistry in order to study tumor and tumor-stromal cell interactions. more
HLA-A
major histocompatibility complex, class I, A
total:8
Long-term engraftment and expansion of tumor-derived memory T cells following the implantation of non-disrupted pieces of human lung tumor into NOD-scid IL2Rgamma(null) mice. 2008 to the paper
Santa Cruz Biotechnology anti-HLA-A(A-18) antibody was used to perform immunohistochemistry in order to study tumor and tumor-stromal cell interactions. more
HLA-C
major histocompatibility complex, class I, C
total:7
Identification of major histocompatibility complex class I C molecule as an attachment factor that facilitates coronavirus HKU1 spike-mediated infection. 2009 to the paper
Invitrogen Purified goat IgG was used as the isotypic controls in order to identify the MHC I molecule (HLA-C) as an attachment factor in facilitating HCoV-HKU1 spike (S) mediated infection. more
HLA-C
major histocompatibility complex, class I, C
total:7
Identification of major histocompatibility complex class I C molecule as an attachment factor that facilitates coronavirus HKU1 spike-mediated infection. 2009 to the paper
Invitrogen Purified goat IgG was used as the isotypic controls in order to identify the MHC I molecule (HLA-C) as an attachment factor in facilitating HCoV-HKU1 spike (S) mediated infection. more
HLA-C
major histocompatibility complex, class I, C
total:7
Identification of major histocompatibility complex class I C molecule as an attachment factor that facilitates coronavirus HKU1 spike-mediated infection. 2009 to the paper
Invitrogen Purified goat IgG was used as the isotypic controls in order to identify the MHC I molecule (HLA-C) as an attachment factor in facilitating HCoV-HKU1 spike (S) mediated infection. more
HLA-C
major histocompatibility complex, class I, C
total:7
Identification of major histocompatibility complex class I C molecule as an attachment factor that facilitates coronavirus HKU1 spike-mediated infection. 2009 to the paper
Invitrogen Purified goat IgG was used as the isotypic controls in order to identify the MHC I molecule (HLA-C) as an attachment factor in facilitating HCoV-HKU1 spike (S) mediated infection. more
HLA-C
major histocompatibility complex, class I, C
total:7
Identification of major histocompatibility complex class I C molecule as an attachment factor that facilitates coronavirus HKU1 spike-mediated infection. 2009 to the paper
Invitrogen Purified goat IgG was used as the isotypic controls in order to identify the MHC I molecule (HLA-C) as an attachment factor in facilitating HCoV-HKU1 spike (S) mediated infection. more
HLA-C
major histocompatibility complex, class I, C
total:7
Identification of major histocompatibility complex class I C molecule as an attachment factor that facilitates coronavirus HKU1 spike-mediated infection. 2009 to the paper
Invitrogen Purified goat IgG was used as the isotypic controls in order to identify the MHC I molecule (HLA-C) as an attachment factor in facilitating HCoV-HKU1 spike (S) mediated infection. more
HLA-C
major histocompatibility complex, class I, C
total:7
Identification of major histocompatibility complex class I C molecule as an attachment factor that facilitates coronavirus HKU1 spike-mediated infection. 2009 to the paper
Invitrogen Purified goat IgG was used as the isotypic controls in order to identify the MHC I molecule (HLA-C) as an attachment factor in facilitating HCoV-HKU1 spike (S) mediated infection. more
HLA-C
major histocompatibility complex, class I, C
total:7
Identification of major histocompatibility complex class I C molecule as an attachment factor that facilitates coronavirus HKU1 spike-mediated infection. 2009 to the paper
Invitrogen Purified goat IgG was used as the isotypic controls in order to identify the MHC I molecule (HLA-C) as an attachment factor in facilitating HCoV-HKU1 spike (S) mediated infection. more
HLA-C
major histocompatibility complex, class I, C
total:7
Identification of major histocompatibility complex class I C molecule as an attachment factor that facilitates coronavirus HKU1 spike-mediated infection. 2009 to the paper
Invitrogen Purified goat IgG was used as the isotypic controls in order to identify the MHC I molecule (HLA-C) as an attachment factor in facilitating HCoV-HKU1 spike (S) mediated infection. more
HLA-C
major histocompatibility complex, class I, C
total:7
Identification of major histocompatibility complex class I C molecule as an attachment factor that facilitates coronavirus HKU1 spike-mediated infection. 2009 to the paper
Invitrogen Purified goat IgG was used as the isotypic controls in order to identify the MHC I molecule (HLA-C) as an attachment factor in facilitating HCoV-HKU1 spike (S) mediated infection. more
HLA-C
major histocompatibility complex, class I, C
total:7
Identification of major histocompatibility complex class I C molecule as an attachment factor that facilitates coronavirus HKU1 spike-mediated infection. 2009 to the paper
Invitrogen Purified goat IgG was used as the isotypic controls in order to identify the MHC I molecule (HLA-C) as an attachment factor in facilitating HCoV-HKU1 spike (S) mediated infection. more
HLA-C
major histocompatibility complex, class I, C
total:7
Identification of major histocompatibility complex class I C molecule as an attachment factor that facilitates coronavirus HKU1 spike-mediated infection. 2009 to the paper
Invitrogen Purified goat IgG was used as the isotypic controls in order to identify the MHC I molecule (HLA-C) as an attachment factor in facilitating HCoV-HKU1 spike (S) mediated infection. more
HLA-F
major histocompatibility complex, class I, F
total:1
Progressive myopathy and defects in the maintenance of myotendinous junctions in mice that lack talin 1 in skeletal muscle. 2008 to the paper
Sigma mouse monoclonal MHCf antibody was used in immunohistochemistry in order to study the role of talin 1 in the development and function of skeletal muscle
IFI27
interferon alpha inducible protein 27
IFI35
interferon induced protein 35
IFI6
interferon alpha inducible protein 6
IFIT1
interferon induced protein with tetratricopeptide repeats 1
IFIT2
interferon induced protein with tetratricopeptide repeats 2
IFIT3
interferon induced protein with tetratricopeptide repeats 3
total:1
Mycobacterial disease and impaired IFN-? immunity in humans with inherited ISG15 deficiency. 2012 to the paper
BD Biosciences anti-IFIT3 antibody was used to perform western blot in order to show that ISG15 deletion in humans impairs IFN-gamma immunity and results in mycobacterial disease susceptibility.
IFITM1
interferon induced transmembrane protein 1
total:1
Cooperativity of the MUC1 oncoprotein and STAT1 pathway in poor prognosis human breast cancer. 2010 to the paper
Proteintech Group anti-IFITM1 antibody was used to perform immunoblot in order to study the interaction between MUC1-C and STAT1 pathway in poor prognosis human breast cancers.
IFITM2
interferon induced transmembrane protein 2
IFITM3
interferon induced transmembrane protein 3
IFNA1
interferon alpha 1
total:11
The VP35 protein of Ebola virus impairs dendritic cell maturation induced by virus and lipopolysaccharide.. 2010 to the paper
PBL Laboratories anti-IFNalpha antibody was used in flow cytometry in order to investigate the role of VP35 Protein of Ebola Virus in the regulation of dendritic cell maturation induced by virus and lipopolysaccharide. more
IFNA10
interferon alpha 10
IFNA14
interferon alpha 14
IFNA16
interferon alpha 16
IFNA17
interferon alpha 17
IFNA21
interferon alpha 21
IFNA4
interferon alpha 4
IFNA5
interferon alpha 5
IFNA6
interferon alpha 6
IFNA7
interferon alpha 7
IFNA8
interferon alpha 8
IFNAR1
interferon alpha and beta receptor subunit 1
total:4
A phosphorylation-acetylation switch regulates STAT1 signaling. 2009 to the paper
Santa Cruz Biotechnology IFNAR1 antibody was used for western blot in order to investigate the role of phosphorylation-acetylation switch in the regulation of STAT1 signaling. more
IFNAR2
interferon alpha and beta receptor subunit 2
total:4
A phosphorylation-acetylation switch regulates STAT1 signaling. 2009 to the paper
Santa Cruz Biotechnology IFNAR2 antibody was used for western blot in order to investigate the role of phosphorylation-acetylation switch in the regulation of STAT1 signaling. more
IFNB1
interferon beta 1
total:9
Inhibition of RIG-I and MDA5-dependent antiviral response by gC1qR at mitochondria. 2009 to the paper
Biosource ELISA kit for IFN-beta was used to measure IFN-beta level in order to study the effect of gC1qR on RIG-I and MDA5-dependent antiviral response at mitochondria. more
IP6K2
inositol hexakisphosphate kinase 2
IRF-1
interferon regulatory factor 1
total:14
Interferon regulatory factor 4 is involved in Epstein-Barr virus-mediated transformation of human B lymphocytes. 2008 to the paper
Santa Cruz Biotechnology anti-IRF-1 antibody was used to perform western blot and immunohistochemical in order to study epstein-barr virus (EBV) infection of human B lymphocytes with interferon regulatory factor 4 (IRF-4). more
IRF-2
interferon regulatory factor 2
total:7
Interferon regulatory factor 4 is involved in Epstein-Barr virus-mediated transformation of human B lymphocytes. 2008 to the paper
Santa Cruz Biotechnology anti-IRF-2 antibody was used to perform western blot and immunohistochemical in order to study epstein-barr virus (EBV) infection of human B lymphocytes with interferon regulatory factor 4 (IRF-4). more
IRF-3
interferon regulatory factor 3
total:22
DNA-PK is a DNA sensor for IRF-3-dependent innate immunity. 2012 to the paper
Life Technologies anti-IRF-3antibody was used to perform western blot in order to study IRF-3-dependent innate immunity more
IRF4
interferon regulatory factor 4
total:6
Frequent expression of multiple myeloma 1/interferon regulatory factor 4 in Burkitt lymphoma. 2009 to the paper
Dako anti-MUM-1/IRF4 antibody (clone:MUM1P) was used in immunohistochemistry to analyze the expression pattern of MUM1, bcl-6, and CD138 along with the association of EBV in 222 well-characterized cases of BL. more
IRF5
interferon regulatory factor 5
total:1
Differential requirement of histone acetylase and deacetylase activities for IRF5-mediated proinflammatory cytokine expression. 2010 to the paper
Abcam goat anti-IRF5 polyclonal antibody was used to perform immunoprecipitation in order to show that IRF5 mediated the transcriptional induction of proinflammatory cytokine expression in conjunction with HATs and HDACs.
IRF6
interferon regulatory factor 6
total:3
Human ?-defensin 6 promotes mucosal innate immunity through self-assembled peptide nanonets. 2012 to the paper
Difco anti-LPS was used to perform immunocytochemistry in order to show that mucosal innate immunity could be promoted by HD6 self-assembly. more
IRF7
interferon regulatory factor 7
total:4
Activation of anti-hepatitis C virus responses via Toll-like receptor 7. 2006 to the paper
Santa Cruz anti-IRF-7 antibody was used to perform western blot in order to study the mechanism of anti-HCV by TLR7 more
IRF8
interferon regulatory factor 8
total:4
IRF-8/interferon (IFN) consensus sequence-binding protein is involved in Toll-like receptor (TLR) signaling and contributes to the cross-talk between TLR and IFN-gamma signaling pathways. 2006 to the paper
Santa Cruz Biotechnology anti-IRF-8 antibody was used in western blot to detect IRF-8 in RAW264.7 cells activated with IFN-gamma, LPS, PGN, and poly (I:C). more
IRF9
interferon regulatory factor 9
total:1
Sendai virus C protein plays a role in restricting PKR activation by limiting the generation of intracellular double-stranded RNA. 2008 to the paper
Santa Cruz Biotechnology anti-IRF9 antibody was used to perform western blot in order to show that SeV C protein can limit generation of dsRNA to restrict PKR activation.
ISG15
ISG15 ubiquitin like modifier
total:7
Mycobacterial disease and impaired IFN-? immunity in humans with inherited ISG15 deficiency. 2012 to the paper
Santa Cruz Biotechnology anti-ISG15 was used to perform flow cytometry and immunocytochemistry in order to show that ISG15 deletion in humans impairs IFN-gamma immunity and results in mycobacterial disease susceptibility. more
ISG20
interferon stimulated exonuclease gene 20
Jak1
Janus kinase 1
total:22
Identification of human thioredoxin as a novel IFN-gamma-induced factor: mechanism of induction and its role in cytokine production. 2008 to the paper
Santa Cruz anti-Jak1 and anti-p-Jak1 were used to perform western blot in order to show that thioredoxin is an IFN-gamma-induced factor and plays a role for cytokine production. more
MX2
MX dynamin like GTPase 2
MxA
MX dynamin like GTPase 1
OAS1
2'-5'-oligoadenylate synthetase 1
total:2
A phylogenetically conserved RNA structure in the poliovirus open reading frame inhibits the antiviral endoribonuclease RNase L. 2007 to the paper
Abgent polyclonal rabbit antibodies against OAS1 were used to perform western blot in order to investigate the role of an RNA structure in the 3C protease ORF of poliovirus. more
OAS2
2'-5'-oligoadenylate synthetase 2
OAS3
2'-5'-oligoadenylate synthetase 3
PSMB8
proteasome 20S subunit beta 8
total:3
Immunoproteasome LMP2 60HH variant alters MBP epitope generation and reduces the risk to develop multiple sclerosis in Italian female population. 2010 to the paper
Affinity-Biomol International anti-LMP7 antibody was used for immunohistochemistry to study the effect of immunoproteasome on the Multiple Sclerosis. more
RNASEL
ribonuclease L
SHP-1
protein tyrosine phosphatase non-receptor type 6
total:16
The Src family kinase, Lyn, suppresses osteoclastogenesis in vitro and in vivo. 2009 to the paper
Santa Cruz Biotechnology anti-SHP-1 polyclonal antibody was used in western blot in order to demonstrate that Lyn can inhibit osteoclast formation. more
SHP-2
protein tyrosine phosphatase non-receptor type 11
total:34
Autoamplification of Notch signaling in macrophages by TLR-induced and RBP-J-dependent induction of Jagged1. 2010 to the paper
Santa Cruz Biotechnology polyclonal anti-Shp2 antibody was used to perform western blot in order to study Notch signaling auto-amplification in macrophages which was regulated by TLR and RBP-J. more
SOCS3
suppressor of cytokine signaling 3
total:10
Unique early gene expression patterns in human adult-to-adult living donor liver grafts compared to deceased donor grafts. 2009 to the paper
Santa Cruz Biotech SOCS3 antibody was used in immunohistochemistry to study the distinctive differences at the molecular level between deceased donor (DD) and living donor (LD) liver grafts more
STAT1
signal transducer and activator of transcription 1
total:84
T-cell/histiocyte-rich large B-cell lymphoma shows transcriptional features suggestive of a tolerogenic host immune response. 2010 to the paper
Santa Cruz Biotechnology anti-STAT1 polyclonal antibody was used to perform immunohistochemistry in order to study the transcriptional features of T-cell/histiocyte-rich large B-cell lymphoma. more
STAT2
signal transducer and activator of transcription 2
total:11
A phosphorylation-acetylation switch regulates STAT1 signaling. 2009 to the paper
Santa Cruz Biotechnology STAT2 antibody was used for western blot in order to investigate the role of phosphorylation-acetylation switch in the regulation of STAT1 signaling. more
Tyk2
tyrosine kinase 2
total:13
Z3, a novel Jak2 tyrosine kinase small-molecule inhibitor that suppresses Jak2-mediated pathologic cell growth. 2008 to the paper
Santa Cruz Biotechnology anti-Tyk2 and anti-p-Tyk2 polyclonal antibodies were used to perform immunoprecipitation and western blot assays in order to demonstrate that Z3 is a novel specific inhibitor that can suppresses Jak2-mediated pathologic cell growth. more
UBP43
ubiquitin specific peptidase 18
XAF1
XIAP associated factor 1